Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call. The company’s CEO, Andrew Dudum, said in the earnings call that it was “currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing.” Dudum said in the call that the company...
Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call. The company’s CEO, Andrew Dudum, said in the earnings call that it was “currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing.” Dudum said in the call that the company...
<iframe src="https://statesidedaily.com/embed/cluster/b06b5a48d994faa576b180a62696b110e3d2ee6b" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Hims & Hers planning to sell compounded peptides"></iframe>
